Results 71 to 80 of about 168,585 (146)

Correction to "Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone". [PDF]

Ann Gastroenterol Surg
europepmc   +1 more source

Quality of life and psychological outcomes with albumin-bound paclitaxel-carboplatin versus solvent-based paclitaxel-carboplatin as first-line chemotherapy in stage IC-IV ovarian carcinoma. [PDF]

Gynecol Oncol Rep
Mahlawat N, Sood A, Vias P, Sawaraj S.
europepmc   +1 more source

Real-World Outcomes of Weekly Paclitaxel-Carboplatin-Based Chemoradiotherapy Versus Cisplatin-Based Chemoradiotherapy for FIGO Stage IB2-IVA Cervical cancer: A Retrospective Observational Study. [PDF]

J Obstet Gynaecol Res
Shimizu A, Chikazawa K, Fukuda Y, Imai K, Shirai K, Kuwata T.   +5 more
europepmc   +1 more source

Paclitaxel induces NM2-dependent cellular contraction through GEF-H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells. [PDF]

Mol Oncol
Asensio-Juárez G, Pérez-Díaz R, Ramos-Solano H, Garrido-Casado M, Talayero VC, Vicente-Manzanares M.   +5 more
europepmc   +1 more source

VASN Enhances IGF2BP3 Stability via USP10 Deubiquitination to Promote Triple-negative Breast Cancer Paclitaxel Resistance. [PDF]

Int J Biol Sci
Liu H, Lu Z, Chen M, Li Z, Chen J, Yang X, Wan X, Tu G, Liu M, Tang L.   +9 more
europepmc   +1 more source

Disruption of microtubules with low intensity ultrasound rescues hair follicle damage by paclitaxel in mouse models. [PDF]

Nat Commun
Amaya C, Luo S, Smith ER, Cheret J, Schlumbrech MP, Wikramanayake TC, Paus R, Xu XX.   +7 more
europepmc   +1 more source

Integrative analysis of FAERS, network toxicology, and Mendelian randomization identifies potential targets in paclitaxel-associated systemic sclerosis. [PDF]

Front Immunol
Wang X, Zhang C.
europepmc   +1 more source

Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial. [PDF]

Clin Pharmacol Drug Dev
Kuchimanchi M, Jørgensen TL, Hanze E, Jain A, Alskär O, Zub O, Shahin MS, Koliadi A, Pothuri B, Krivak T, Pishchyk M, Segev Y, Backes FJ, Gennigens C, Bouberhan S, Zajic S, Melhem M, Buscema J.   +17 more
europepmc   +1 more source

Bevacizumab plus nab-paclitaxel and platinum as second-line therapy for driver-gene-negative non-squamous non-small cell lung cancer after immunochemotherapy: A prospective single-arm single-centre study. [PDF]

Clin Transl Med
Lin Y, Yu Y, Hu Z, Wei C, Wang Z, Zhang Y, Wu Z, Yu B, Zhao X, Yu H, Wu X, Wang H, Wang J.   +12 more
europepmc   +1 more source

Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA. [PDF]

Int J Womens Health
Liu Y, Xu M, Ma J, Zhu Y, Gao M.
europepmc   +1 more source